Since the initial studies of receptor-mediated endocytosis on LDL (1, 2 ) and asialoglycoprotein (ASGP) (3, 4 ), many internalized ligands and their receptors have been identified and characterized (5 ). It was soon recognized that these receptors could be exploited for pharmaceutical and medical imaging applications (6 ). In the case of the ASGP receptor (ASGP-R), delivery of diagnostic or therapeutic agents to hepatocytes was achieved by attachment of the agent to a variety of macromolecules possessing the terminal galactose signal necessary to bind the ASGP-R (6 ). These moieties include radioactive isotopes (7 ), drugs (8 ), and DNA (9 ).
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Considering the effort devoted to developing drug delivery systems utilizing the ASGP-R, surprisingly little effort has been devoted to developing simple, easy-to-use assays to measure this receptor activity in vivo. Much of the technology associated with receptor-based diagnostic agents has arisen in fields associated with magnetic resonance and single photon emission computed tomography imaging. One class of magnetic resonance compounds includes iron chelates, which appear to be absorbed by hepatocytes by an unknown biochemical mechanism (10 ) . Saini et al. (11 ) and others have demonstrated the promise of ferrite particles as a magnetic resonance contrast agent for liver imaging. These commercially available micron-sized particles are taken up by the Kupffer cells of liver and do not measure ASGP-R activity.
Sato et al. (12 ) reported on the ability of the ASGP-R to take up galactose-terminated, protein-coated ferrite particles in vivo. These particles are taken up preferentially by hepatocytes (70%) and largely avoid uptake by the reticular endothelial system. For a crystal-based material to bind the ASGP-R of hepatocytes, it must penetrate pores of the 100-nm fenestrae characteristic of endothelial cells that lie between the hepatocyte and the circulatory compartment (13 ) . Particles smaller than 100 nm are needed to serve as hepatocyte-directed diagnostic agents. Josephson et al. (14 ) developed the findings of Sato et al. (12 ) by synthesizing a superparamagnetic iron oxide colloid (ϳ50 nm) coated with the polygalactosylated polysaccharide arabinogalactan. This colloid cleared rapidly from the vascular system; its clearance was inhibited by asialofetuin but not by fetuin, indicative of ASGP-R interaction. More than 90% of the particles were taken up in hepatocytes.
The most thoroughly studied ASGP-R-directed agents are those based on galactosylated albumin labeled with radioactive technetium ( 99m Tc) (15) (16) (17) (18) (19) . Although the use of Tc-galactosylated albumin offers a unique and elegant approach to the study of liver biology, its application in the research laboratory and the clinic is limited. Many investigators have limited access to 99 Tc generators and would prefer to avoid the use of radioactivity. In the clinic, radioactivity presents a potential hazard to the patient and medical personnel. 99 Tc scintigraphy also relies on expensive instrumentation.
Stable-isotope labeling offers a cost-effective technology to deal with measuring the ASGP-R activity and biodistribution in vivo (20 ) . This report explores the feasibility of using stable-isotope labeling of ASGP-R-directed agents for measuring ASGP-R activity in vivo. Two examples of such labels are reported-arabinogalactan labeled with samarium and gold colloids coated with lactosylated albumin-and their specificity for the ASGP-R and sensitivity are explored.
Unless stated otherwise, all reagents were obtained from Sigma-Aldrich. The diethylenetriaminepentaacetic acid (DTPA) conjugate of arabinogalactan was prepared as described previously (21 ) . The final product contained 4.7 moles of DTPA per mole of arabinogalactan. The samarium chelate of arabinogalactan (Sm-arabinogalactan) was prepared from a solution of samarium chloride (0.3 mmol), adjusted to pH 2, that was added to DTPAarabinogalactan (0.1 mmol), also adjusted to pH 2, in saline. The solution was adjusted to pH 5, mixed for 30 min, and adjusted to pH 7.4. PolyGalactoseGold TM colloidal gold (20 nm) and lactosylated albumin (1 g/L) were incubated for 2 h at room temperature in 0.01 mol/L bicarbonate buffer, pH 8.5. Colloidal gold was isolated by centrifugation and suspended in phosphate-buffered saline. Albumin-coated gold colloid was prepared by substituting bovine albumin for lactosylated albumin. The coating and stability of each colloid was evidenced by the suspension remaining red in the presence of saline (a light-scattering color consistent with a 20-nm particle size). In contrast, uncoated colloidal gold suspended in saline turned purple and a precipitate formed.
The stability of Sm-arabinogalactan was evaluated in rat serum by incubation for 60 min at 37°C followed by analysis using size-exclusion chromatography (Sephadex G-50). All of the samarium was retained in the fractions corresponding to arabinogalactan.
Rats (300 -375 g) used in all studies were male hooded/ BBZDR (BioMedical Research Models). For each set of experiments, three rats were anesthetized with Nembutal. The carotid artery and jugular vein were exposed, and the animal received via the jugular vein an injection of Sm-arabinogalactan (4 mg/kg), PolyGalactoseGold (50 g/kg), or albumin-coated gold (50 g/kg). A second set of animals received injections of asialofetuin (100 mg/kg) followed by Sm-arabinogalactan or PolyGalactoseGold. At various times, blood samples were removed from the carotid artery. After 60 min, the animals were sacrificed, and ϳ1-g amounts of various tissues were recovered for quantification of samarium or gold. Tissues were blotted to remove blood and clots. No additional processing of tissue such as perfusion was necessary to perform neutron activation analysis.
The samarium and gold content in all samples was quantified by neutron activation by BioPAL (Worcester, MA; www.biopal.com). Samples were placed in 2-mL Clinical Chemistry 46, No. 9, 2000 polypropylene tubes free of trace element contaminants and dried at 70°C for a minimum of 12 h. An internal standard of tungsten, to correct for variations in neutron flux, was added to each sample. Samples were activated for 15 min in a neutron field created by a 2-MW nuclear reactor. Short-lived activated products, principally resulting from sodium and chloride, were allowed to decay for 2 days, and the remaining radioactivity from activated samarium or gold was counted using a high-resolution gamma spectrometer.
The fate of Sm-arabinogalactan after intravenous injection into rats was examined by obtaining the biodistribution of the conjugate 60 min after injection. Biodistribution of the conjugate was inferred by the presence of samarium in tissues after the injection of Sm-arabinogalactan. Smarabinogalactan was present in the liver (51% of injected dose) and urine (35% of injected dose). Less than 1% of the injected dose was present in spleen or blood. When asialofetuin, a ligand for the ASGP-R of hepatocytes, was co-injected with Sm-arabinogalactan, hepatic uptake decreased to 3%, whereas the urine fraction increased to 52%. Asialofetuin also increased blood concentrations of Sm-arabinogalactan from 1% to 17%, which increased urinary elimination. Biodistribution data and inhibition of hepatic uptake by asialofetuin indicated that the hepatic clearance of Sm-arabinogalactan was mediated by the ASGP-R. Renal clearance of Sm-arabinogalactan is consistent with the conjugate's low molecular mass (ϳ40 kDa) and compact globular shape allowing excretion by glomerular filtration.
The fate of PolyGalactoseGold after intravenous injection into rats and mice was examined by obtaining the biodistribution of the conjugate 60 min after injection. Biodistribution of the conjugate was inferred by the presence of gold in tissues after the injection of PolyGalactoseGold. PolyGalactoseGold was present in the liver (ϳ100% of injected dose) but not in the spleen, adrenals, lung, kidney, heart, marrow, brain, muscle, or urine. When asialofetuin, a ligand for the ASGP-R of hepatocytes, was co-injected with PolyGalactoseGold, blood clearance was substantially slower (Fig. 1) . When albumin-coated colloidal gold was substituted for PolyGalactoseGold, blood clearance for albumin-coated gold was also substantially slower than that seen with PolyGalactoseGold, demonstrating the specific role of galactose for clearing PolyGalactoseGold. These results are consistent with reports in the literature that lactosylated albumin is a ligand of the ASGP-R and indicate that the hepatic clearance of PolyGalactoseGold was mediated by the ASGP-R. The lack of renal clearance of PolyGalactoseGold is consistent with its size (20 nm), which corresponds to a molecule approximately the size of IgM. With the activation procedure described above, 1 ng of gold corresponding to ϳ800 dpm could be easily distinguished from background (ϳ5 dpm).
We hypothesize that a compound consisting of a stable isotope bound to a receptor-directed reagent can be assayed with neutron activation technology to study and evaluate hepatic function. As a first step we characterized two ASGP-R-directed reagents labeled with a stable isotope of either samarium or gold, each possessing excellent properties for neutron activation. This approach presents an alternative to existing methods used to measure ASGP-R activity using radioactive, magnetic, or dyelabeled agents. Rats received injections of gold colloid coated with lactosylated albumin in the absence (f) or presence of asialofetuin (F) or with gold colloid coated with albumin (OE). Blood samples were drawn at the indicated times, and the percentage of gold remaining in the blood (normalized for gold concentration at time zero) was determined using neutron activation analysis. Values presented represent the mean value obtained with three rats. Mean (SD) values for samples were calculated using the percentages of gold remaining in the blood. Standard deviations are therefore not calculated for values of 100%. Mean (SD) values at 5, 10, and 15 min were as follows: lactosylated albumin-coated gold colloid, 33% (6.1%) and 8% (1.0%); lactosylated albumin-coated gold colloid in the presence of asialofetuin, 95% (1.7%), 43% (3.6%), and 9% (2.0%); albumincoated gold colloid, 100%, 75% (5.2%), and 42% (6.2%). Determining the presence of TnI in the serum of patients is an important aid in the diagnosis of myocardial infarction. An advantage of TnI is its improved specificity for myocardial damage compared with creatine kinase-MB (1 ). In addition, there is strong evidence that future utilization of TnI will be for risk stratification to assist in the decision process for therapeutic intervention with glycoprotein II/IIIa inhibitors or low-molecular weight heparin (2, 3 ) . In fact, the GUSTO trial, which should be completed soon, included TnI as one of the cardiac markers to be considered for risk stratification. The cardiac troponin complex is part of the contractile apparatus of the thin filament in striated muscle and consists of subunits C, T, and I. Different isoforms of TnI exist in the skeletal and cardiac muscles (fast skeletal, slow skeletal, and cardiac TnI). The distinct structural heterogeneity between these isoforms allows production of specific antibodies (4 ), which can be utilized by the latex assay to detect serum TnI in clinical conditions that involve myocardial damage. After acute myocardial infarction, damaged myocytes lose these proteins, and various forms of troponin (complexed, free, or fragments) appear in the blood (5 ) . TnI concentrations become abnormal 4 -8 h after the onset of chest pain, peak at 12-16 h, and remain increased for 5-9 days following an infarction.
Development of an
We have developed an automated latex immunoassay for the detection of TnI in serum with excellent sensitivity, precision, and stability. The assay utilizes two monoclonal antibodies and one polyclonal antibody to TnI. Antibodies were selected using Biacore analysis, epitope mapping, and pairing studies. Each antibody was separately covalently bound to 200-nm supercarboxyl polystyrene latex particles using 1-ethyl-3(3-dimethylaminopropyl)carbodiimide hydrochloride in a two-step coupling process. The various coupled antibodies were then combined into one solution in a 1:1:1 ratio. Unbound antibody was removed with a microgon system, which utilizes tangential flow. The beads were then sonicated to redistribute the particles. When TnI is present in the serum, the addition of a reaction buffer causes adjacent beads to cross-link, increasing the turbidity of the solution. The results are calculated in Ͻ9 min by the Cobas Mira from a stored calibration curve generated with recombinant human cardiac TnI calibrators using a logit/log4 calculation mode. Reaction buffer (140 L), water (10 L), and latex (45 L of a 1.25 g/L solution) are mixed and incubated at 37°C for 125 s. Sample (30 L) and water (5 L) are then added, and the absorbance change of the reaction mixture is measured from ϳ1 min 25 s to ϳ8 min after the addition of sample. The rate of increase in turbidity, measured at 600 nm, is proportional to the concentration of TnI present in the serum. The assay range was 0 -25 g/L. The detection limit of the assay was 0.3 g/L. This value was calculated as 2 SD above the mean of 21 replicates of the zero calibrator. Using NCCLS guidelines, intra-and interassay imprecision was determined using both a high and low control over a course of 18 days with two analytical runs per day. The intraassay imprecision (CV) for the 5 g/L control was 6.8%, and its interassay CV was 7.5%. The 15 g/L control gave an intraassay CV of 1.6% and interassay CV of 4.2%.
Stability studies were carried out on the latex particles, the assay buffer, and the calibrators by evaluating the performance of high and low controls with the test reagent at scheduled intervals with approved lots of reagents. The test reagent was considered unstable when the control results demonstrated a downward or upward shift of Ͼ10% from the day 0 value for the control and this variation was consistent on 2 or more consecutive days. Calibrators were found to be stable for 2 months when stored at room temperature. Latex reagent was stable for 21 days at 37°C, and the reaction buffer was stable for 56 days at room temperature.
The assay was evaluated to determine whether antigenexcess phenomenon (prozone effect) would cause false negatives. A false negative occurs when a sample that has a high troponin concentration produces a negative result instead of the high value. This phenomenon was evaluated by preparing a high concentration of recombinant TnI in storage buffer, making serial dilutions of this
